Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09 2024 - 8:00AM
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a
biopharmaceutical company focused on developing novel therapeutics
for serious chronic gastrointestinal (GI) diseases, today announced
that its abstract has been accepted for poster presentation at the
Crohn’s & Colitis Congress being held January 25-27, 2024 in
Las Vegas, NV.
Details of the poster presentation are as
follows:
Session: Poster Sessions and
ReceptionPoster Title: Local Bioactivation and
Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for
Ulcerative Colitis Treatment Session Dates and
Times: January 26, 2024 from 7:00 PM to 8:00 PM PST (UTC
-8)Presentation Location: Bellagio Ballroom
For more information about the congress, please
visit crohnscolitiscongress.org.
About Palisade Bio Palisade Bio
is a biopharmaceutical company focused on developing novel
therapeutics for serious chronic gastrointestinal diseases. The
Company believes that by using a targeted approach with its novel
therapeutics it will transform the treatment landscape. For more
information, please go to www.palisadebio.com.
Forward Looking StatementsThis
communication contains “forward-looking” statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the extent of our cash runway; our ability to successfully develop
our licensed technologies; estimates about the size and growth
potential of the markets for our product candidates, and our
ability to serve those markets, including any potential revenue
generated; future regulatory, judicial, and legislative changes or
developments in the United States (U.S.) and foreign countries and
the impact of these changes; our ability to maintain the Nasdaq
listing of our securities; our ability to build a commercial
infrastructure in the U.S. and other markets; our ability to
compete effectively in a competitive industry; our ability to
identify and qualify manufacturers to provide API and manufacture
drug product; our ability to enter into commercial supply
agreements; the success of competing technologies that are or may
become available; our ability to attract and retain key scientific
or management personnel; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for
additional financing; our ability to obtain funding for our
operations; our ability to attract collaborators and strategic
partnerships; and the impact of the COVID-19 pandemic or any global
event on our business, and operations, and supply. Any statements
contained in this communication that are not statements of
historical fact may be deemed to be forward-looking statements.
These forward-looking statements are based upon the Company’s
current expectations. Forward-looking statements involve risks and
uncertainties. The Company’s actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the Company’s
ability to advance its nonclinical and clinical programs, the
uncertain and time-consuming regulatory approval process; and the
Company’s ability to secure additional financing to fund future
operations and development of its product candidates. Additional
risks and uncertainties can be found in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2022, filed
with the Securities and Exchange Commission (“SEC”) on March 22,
2023, as well as the Company’s Quarterly Report on Form 10-Q, for
the three and nine month periods ended September 30, 2023, filed
with the SEC on November 9, 2023. These forward-looking statements
speak only as of the date hereof and the Company expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in the Company’s expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
Investor Relations Contact
JTC Team, LLCJenene Thomas 833-475-8247PALI@jtcir.com
Source: Palisade Bio
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jul 2023 to Jul 2024